Jump to content

PF-05089771

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Aethyta (talk | contribs) at 04:53, 4 September 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

PF-05089771
Legal status
Legal status
  • Investigational New Medicine
Identifiers
  • 4-[2-(3-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H12Cl2FN5O3S2
Molar mass500.34 g·mol−1
3D model (JSmol)
  • C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F
  • InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25)
  • Key:ZYSCOUXLBXGGIM-UHFFFAOYSA-N

PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.[1][2][3] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.[4]

See also

References

  1. ^ McMahon, Stephen B.; Koltzenburg, Martin; Tracey, Irene; Turk, Dennis (March 2013). Wall & Melzack's Textbook of Pain. Elsevier Health Sciences. p. 508. ISBN 0702053740.
  2. ^ Martz, Lauren (June 2014). "Nav-i-gating antibodies for pain". SciBX: Science-Business eXchange. 7 (23). doi:10.1038/scibx.2014.662.
  3. ^ Alexandrou, Aristos J.; Brown, Adam R.; Chapman, Mark L.; Estacion, Mark; Turner, Jamie; Mis, Malgorzata A.; Wilbrey, Anna; Payne, Elizabeth C.; Gutteridge, Alex; Cox, Peter J.; Doyle, Rachel; Printzenhoff, David; Lin, Zhixin; Marron, Brian E.; West, Christopher; Swain, Nigel A.; Storer, R. Ian; Stupple, Paul A.; Castle, Neil A.; Hounshell, James A.; Rivara, Mirko; Randall, Andrew; Dib-Hajj, Sulayman D.; Krafte, Douglas; Waxman, Stephen G.; Patel, Manoj K.; Butt, Richard P.; Stevens, Edward B. (6 April 2016). "Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release". PLOS ONE. 11 (4): e0152405. doi:10.1371/journal.pone.0152405. ISSN 1932-6203. PMC 4822888. PMID 27050761.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Storer, R. Ian; Swain, Nigel A. (15 August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.